Continuous intravenous infusion of TRH-T: Clinical, cardiovascular and endocrinological effects

R. Formisano, S. Ruggieri, R. Cerbo, F. Lucarelli, G. De Vuono, M. Parmegiani, A. Agnoli, A. Attanasio, A. Capria, C. G C Piccolo, E. Fabrizi, D. Cannata

Research output: Contribution to journalArticle

Abstract

Seven patients, six suffering from amyotrophic lateral sclerosis (ALS) and one from Friedreich ataxia, were treated with a placebo i.v. infusion during the first day and with TRH-T i.v. infusion at a rate of 2 mg/h for 8 h daily (total daily dosage 16 mg) on the 2 consecutive days. Continuous blood pressure (BP) and EKG monitorings were performed during 3 days infusion. Blood samples were collected for endocrinological evaluations. The neurological evaluation after acute TRH-T treatment showed an objective improvement in 3 of the 8. We found significantly higher values of systolic (max. difference of 10.1 mm Hg) and diastolic (max. difference of 8.8 mmHg) BP than during placebo, beginning from the 5th h of the infusion (p <0.05). A trend in progressive increase of the heart rate (HR) reached statistical significance (p <0.01) at the 8th h of the second TRH-T infusion. The cardiovascular changes during the i.v. continuous TRH-T infusions were clinically irrelevant and never required the interruption of the treatment.

Original languageEnglish
Pages (from-to)514-518
Number of pages5
JournalActa Neurologica Scandinavica
Volume84
Issue number6
Publication statusPublished - 1991

Fingerprint

Intravenous Infusions
Placebos
Blood Pressure
Friedreich Ataxia
Amyotrophic Lateral Sclerosis
Psychological Stress
Electrocardiography
Heart Rate
Therapeutics

Keywords

  • amyotrophic lateral sclerosis
  • cardiovascular effects
  • continuous intravenous infusion
  • TRH-T

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Formisano, R., Ruggieri, S., Cerbo, R., Lucarelli, F., De Vuono, G., Parmegiani, M., ... Cannata, D. (1991). Continuous intravenous infusion of TRH-T: Clinical, cardiovascular and endocrinological effects. Acta Neurologica Scandinavica, 84(6), 514-518.

Continuous intravenous infusion of TRH-T : Clinical, cardiovascular and endocrinological effects. / Formisano, R.; Ruggieri, S.; Cerbo, R.; Lucarelli, F.; De Vuono, G.; Parmegiani, M.; Agnoli, A.; Attanasio, A.; Capria, A.; Piccolo, C. G C; Fabrizi, E.; Cannata, D.

In: Acta Neurologica Scandinavica, Vol. 84, No. 6, 1991, p. 514-518.

Research output: Contribution to journalArticle

Formisano, R, Ruggieri, S, Cerbo, R, Lucarelli, F, De Vuono, G, Parmegiani, M, Agnoli, A, Attanasio, A, Capria, A, Piccolo, CGC, Fabrizi, E & Cannata, D 1991, 'Continuous intravenous infusion of TRH-T: Clinical, cardiovascular and endocrinological effects', Acta Neurologica Scandinavica, vol. 84, no. 6, pp. 514-518.
Formisano R, Ruggieri S, Cerbo R, Lucarelli F, De Vuono G, Parmegiani M et al. Continuous intravenous infusion of TRH-T: Clinical, cardiovascular and endocrinological effects. Acta Neurologica Scandinavica. 1991;84(6):514-518.
Formisano, R. ; Ruggieri, S. ; Cerbo, R. ; Lucarelli, F. ; De Vuono, G. ; Parmegiani, M. ; Agnoli, A. ; Attanasio, A. ; Capria, A. ; Piccolo, C. G C ; Fabrizi, E. ; Cannata, D. / Continuous intravenous infusion of TRH-T : Clinical, cardiovascular and endocrinological effects. In: Acta Neurologica Scandinavica. 1991 ; Vol. 84, No. 6. pp. 514-518.
@article{cc1b8e42f3e147699e69aacabf4f6807,
title = "Continuous intravenous infusion of TRH-T: Clinical, cardiovascular and endocrinological effects",
abstract = "Seven patients, six suffering from amyotrophic lateral sclerosis (ALS) and one from Friedreich ataxia, were treated with a placebo i.v. infusion during the first day and with TRH-T i.v. infusion at a rate of 2 mg/h for 8 h daily (total daily dosage 16 mg) on the 2 consecutive days. Continuous blood pressure (BP) and EKG monitorings were performed during 3 days infusion. Blood samples were collected for endocrinological evaluations. The neurological evaluation after acute TRH-T treatment showed an objective improvement in 3 of the 8. We found significantly higher values of systolic (max. difference of 10.1 mm Hg) and diastolic (max. difference of 8.8 mmHg) BP than during placebo, beginning from the 5th h of the infusion (p <0.05). A trend in progressive increase of the heart rate (HR) reached statistical significance (p <0.01) at the 8th h of the second TRH-T infusion. The cardiovascular changes during the i.v. continuous TRH-T infusions were clinically irrelevant and never required the interruption of the treatment.",
keywords = "amyotrophic lateral sclerosis, cardiovascular effects, continuous intravenous infusion, TRH-T",
author = "R. Formisano and S. Ruggieri and R. Cerbo and F. Lucarelli and {De Vuono}, G. and M. Parmegiani and A. Agnoli and A. Attanasio and A. Capria and Piccolo, {C. G C} and E. Fabrizi and D. Cannata",
year = "1991",
language = "English",
volume = "84",
pages = "514--518",
journal = "Acta Neurologica Scandinavica",
issn = "0001-6314",
publisher = "Wiley Blackwell",
number = "6",

}

TY - JOUR

T1 - Continuous intravenous infusion of TRH-T

T2 - Clinical, cardiovascular and endocrinological effects

AU - Formisano, R.

AU - Ruggieri, S.

AU - Cerbo, R.

AU - Lucarelli, F.

AU - De Vuono, G.

AU - Parmegiani, M.

AU - Agnoli, A.

AU - Attanasio, A.

AU - Capria, A.

AU - Piccolo, C. G C

AU - Fabrizi, E.

AU - Cannata, D.

PY - 1991

Y1 - 1991

N2 - Seven patients, six suffering from amyotrophic lateral sclerosis (ALS) and one from Friedreich ataxia, were treated with a placebo i.v. infusion during the first day and with TRH-T i.v. infusion at a rate of 2 mg/h for 8 h daily (total daily dosage 16 mg) on the 2 consecutive days. Continuous blood pressure (BP) and EKG monitorings were performed during 3 days infusion. Blood samples were collected for endocrinological evaluations. The neurological evaluation after acute TRH-T treatment showed an objective improvement in 3 of the 8. We found significantly higher values of systolic (max. difference of 10.1 mm Hg) and diastolic (max. difference of 8.8 mmHg) BP than during placebo, beginning from the 5th h of the infusion (p <0.05). A trend in progressive increase of the heart rate (HR) reached statistical significance (p <0.01) at the 8th h of the second TRH-T infusion. The cardiovascular changes during the i.v. continuous TRH-T infusions were clinically irrelevant and never required the interruption of the treatment.

AB - Seven patients, six suffering from amyotrophic lateral sclerosis (ALS) and one from Friedreich ataxia, were treated with a placebo i.v. infusion during the first day and with TRH-T i.v. infusion at a rate of 2 mg/h for 8 h daily (total daily dosage 16 mg) on the 2 consecutive days. Continuous blood pressure (BP) and EKG monitorings were performed during 3 days infusion. Blood samples were collected for endocrinological evaluations. The neurological evaluation after acute TRH-T treatment showed an objective improvement in 3 of the 8. We found significantly higher values of systolic (max. difference of 10.1 mm Hg) and diastolic (max. difference of 8.8 mmHg) BP than during placebo, beginning from the 5th h of the infusion (p <0.05). A trend in progressive increase of the heart rate (HR) reached statistical significance (p <0.01) at the 8th h of the second TRH-T infusion. The cardiovascular changes during the i.v. continuous TRH-T infusions were clinically irrelevant and never required the interruption of the treatment.

KW - amyotrophic lateral sclerosis

KW - cardiovascular effects

KW - continuous intravenous infusion

KW - TRH-T

UR - http://www.scopus.com/inward/record.url?scp=0026348240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026348240&partnerID=8YFLogxK

M3 - Article

C2 - 1792854

AN - SCOPUS:0026348240

VL - 84

SP - 514

EP - 518

JO - Acta Neurologica Scandinavica

JF - Acta Neurologica Scandinavica

SN - 0001-6314

IS - 6

ER -